Previous 10 | Next 10 |
Synlogic (NASDAQ: SYBX ) +26% as Ginkgo Bioworks to invest $80M . More news on: Synlogic, Inc., Bridgeline Digital, Inc., MagnaChip Semiconductor Corporation, , Stocks on the move Read more ...
Raymond James has upgraded CymaBay Therapeutics (NASDAQ: CBAY ) to Strong Buy after today's harsh market reaction to experimental data released this morning. More news on: CymaBay Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
CBAY stock is under severe selling pressure after CymaBay Therapeutics Inc (NASDAQ:CBAY) reported interim data from an ongoing Phase 2b clinical trial for seladelpar. Setback for CymaBay California-based CymaBay Therapeutics has had a setback in the Phase 2 trial with its product that w...
Gainers: Jaguar Health (NASDAQ: JAGX ) +60% . ContraVir Pharmaceuticals (NASDAQ: CTRV ) +40% . TORM (NASDAQ: TRMD ) +20% . Rekor Systems, Inc. (REKR) +17% . Enzo Biochem, Inc. (NYSE: ENZ ) +17% . Oxbridge Re Holdings (NASDAQ: OXBR ) +16% . Tenax Therapeutics (NASDAQ: TENX ) +1...
CymaBay Therapeutics (NASDAQ: CBAY ) -45% on disappointing data on NASH candidate seladelpar. More news on: CymaBay Therapeutics, Inc., Achieve Life Sciences, Inc., Beyond Meat, Inc., Stocks on the move, Read more ...
CymaBay Therapeutics (NASDAQ: CBAY ) craters 40% premarket on light volume (so far) in reaction to 12-week data from a Phase 2b clinical trial evaluating seladelpar in patients with nonalcoholic steatohepatitis (NASH). More news on: CymaBay Therapeutics, Inc., Healthcare st...
- Reductions in liver fat were minimal and not significant compared to placebo - Reductions in markers of liver injury were robust and clinically meaningful - Seladelpar appears to be safe and well-tolerated across all doses - Blinded stud...
Cymabay Therapeutics ( CBAY ) has doubled since January, surrounding the high excitement of its upcoming release of phase 2b NASH data for seladelpar, especially given Conatus's ( CNAT ) recent flop. However, it is difficult to make a prediction on the basis of upcoming phase 2 data, so our fo...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 104 weeks of public selections as part of this ongoing live forward-testing. In...
NEWARK, Calif., May 20, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced results related to its seladelpar cl...
News, Short Squeeze, Breakout and More Instantly...
CymaBay Therapeutics Inc. Company Name:
CBAY Stock Symbol:
NASDAQ Market:
CymaBay Therapeutics Inc. Website:
Acquisition Reinforces Gilead’s Leadership in Developing Innovative Therapies For Challenging Liver Diseases Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for appr...
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.06% on the day to $32.49. CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chr...
2024-03-12 10:45:01 ET UiPath Inc (PATH) PATH is trading UP for the last 5 days, and it at trading at $24.64 with volume of 4,269,666 and a one day change of $0.54 (2.25%). UiPath Inc has a 52-week low of 12.38 and a 52-week high of $27.87. The business's 50-day moving average price...